Malignant mixed mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy

Mok, Jung Eun; Kim, Y.M.; Jung, Min Hyung; Kim, K.R.; Kim, D.Y.; Kim, J.H.; Nam, Joo‐Hyun

doi:10.1111/j.1525-1438.2006.00281.x

Cited by 37 publications

(25 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These tumors histologically consist of both carcinomatous and sarcomatous components. Ovarian carcinosarcomas are subclassified as heterologous or homologous, depending on the presence or absence of a stromal component containing mesenchymal tissue not normally found at the primary tumor site [2]. …”

Section: Introductionmentioning

confidence: 99%

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Chun

Kim²,

Kim³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: There have been only a few reports on the survival and management of patients with ovarian carcinosarcomas. We evaluated the clinical characteristics, outcomes and prognostic factors of ovarian carcinosarcomas. Methods: Retrospective analysis of data obtained from medical records of 40 patients treated at the Asan Medical Center, Seoul, Korea, between January 1989 and January 2008. Results: Median survival was significantly longer in patients <60 years of age than in those ≧60 (p = 0.001), patients with early-stage compared to advanced tumors (p = 0.035), those with optimally debulked tumors compared to suboptimally (p < 0.001) in the advanced stage, and patients treated with paclitaxel/platinum compared to patients treated with other chemotherapies (p < 0.001). The progression-free interval was longer in patients with early-stage (p = 0.003) and optimally debulked tumors (p = 0.001), as well as in those treated with paclitaxel/platinum (p = 0.049). Multivariate analysis showed that advanced-stage, non-optimal debulking and non-paclitaxel/platinum chemotherapy were significant independent predictors of a shorter progression-free interval, and that non-optimal debulking and non-paclitaxel/platinum chemotherapy were significant independent predictors of shorter overall survival. Conclusions: Early-stage optimal debulking and adequate chemotherapy can influence time to progression and survival, indicating that the most effective treatment for patients with ovarian carcinosarcomas consists of optimal debulking surgery followed by paclitaxel/platinum chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Chun

Kim²,

Kim³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…In an early study, Sood et al showed that patients with cancers with homologous sarcomatous elements had a significantly better survival compared to those with cancers containing heterologous elements [9]. But recent studies have suggested that there was no correlation and currently sarcomatous type is not considered a prognostic factor [4]. On the other hand, serous epithelial components have been proven to be associated with a worse survival compared to nonserous epithelial components [10].…”

Section: Discussionmentioning

confidence: 99%

“…This was probably due to the small number of our series. Some investigators presumed CA-125 to be a useful marker and integrated this parameter into their studies [4,5]. However, other investigators did not consider the use of CA-125 in their patients [6,7].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Carcinosarcoma of the Ovary: Analysis of 13 Cases and Review of the Literature

et al. 2011

View full text Add to dashboard Cite

Objectives: The aim of this study was to evaluate our experience with patients affected by ovarian carcinosarcoma. Patients and Methods: During a 16-year period, data on 13 patients with ovarian carcinosarcoma were collected. They were obtained from hospital charts and follow-up visits. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. All tests were two-tailed with p values <0.05 considered significant. Results: Our study was conducted on 13 patients with ovarian carcinosarcoma referred to our unit, during an observation time of about 16 years (March 1994 to October 2010). An improved survival was observed in patients treated with optimal cytoreductive surgery with residual tumors <2 cm (30 vs. 5 months; p = 0.042). All patients underwent adjuvant chemotherapy based on the combination of cisplatin, epirubicin and ifosfamide (PEI) and taxol and carboplatin (TAX-CBDCA) regimen. Overall survival of the patient population was 17 months. Conclusions: Similarly to data published in the literature, we observed that malignant mixed mullerian ovarian tumors are very aggressive and are usually diagnosed at an advanced age and at an advanced stage of disease. Therefore, due to the rarity of the tumor we would like to add our series to those already published in the literature, although our treatment recommendations are actually based upon retrospective studies with a small patient population.

show abstract

“…5 Overall survival of patients with MMMT of the fallopian tube was found to be 16.1 months, in one review, and this survival time was similar to that estimated for the malignant mixed Müllerian tumors of the ovary. 6,8 Consequently, carcinosarcomas are highly aggressive tumors and despite all these therapies, their prognosis are still fairly poor. Hence, it was deemed necessary to practice new treatment regimens to improve the survival time.…”

Section: Discussionmentioning

confidence: 99%